ITGAM and neoplasm: GFI administration in the tumor-bearing mice, in the present study, significantly reduced the percentage and number of splenic MDSCs and increased the percentage of CD8+T cells in the spleen, but did not reduce the percentage of CD11b+Gr-1+ MDSCs in the bone marrow.